 | The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. By analyzing R&D pipelines and the platform technologies in use today, it is possible to better predict where the market will be in the next decade and to envisage which new innovative therapies will become market successes. |
|
| There is a plethora of new anti-angiogenic drugs in development. The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have we seen as many anti-angiogenic drugs in clinical trials.This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you. |
|
| The ultimate goal of cancer research is to learn how to make cancer cells selectively die. Apoptosis is the type of death about whose genetically controlled pathways we know the most.Apoptotic cell death can be triggered by many different cellular stimuli, resulting in activation of apoptotic signaling pathways including extrinsic, intrinsic, and mitochondrial pathways. The plethora of new potential therapeutic drugs has made selection and validation of novel molecular targets of paramount importance.First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology. |
|
| All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in which they have occurred. Protein kinases have been implicated in many aspects of tumorigenesis and protein kinase inhibitors (PKIs) have there of arisen as a major therapeutic class of compounds for the treatment of cancer. The plethora of new potential therapeutic drugs have made selection and validation of novel molecular targets of paramount importance. |
|
| This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about. |
|
| The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. In the current alternatives for the treatment of malignant melanoma several combinatory treatments are used. Melanoma drug development has and will continue to have a strong focus on target therapy such as cancer vaccines, monoclonal antibodies, biological drugs, antiangiogenesis, apoptotic inducers and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells and antiangiogenesis. |
|
| The elaborate advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy in cancer. There are currently more than 400 antibody based drugs in development for the treatment of cancer. What and where they are targeting has to date only been a fragmented knowledge. First in place, BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. |
|
| Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world. After several acquisitions and mergers in the market place, BioSeeker offers you the tool to get an updated look on the competitive landscape in oncology, including almost 900 hundred companies in 39 different countries. Global Cancer Focus Company Directory breaks down all companies into their involvement in 81 different cancer indications, also including supportive care and diagnosis. |
|
| Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. New data on platinum-based chemotherapy has been presented. Both Avastin and Efaproxyn have generated additional data. |
|
| The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront. |
|
| Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years. The most dramatic decrease is seen in younger patients (<50 years). In the past decade the regulatory authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal antibody (Herceptin) as a treatment option for breast cancer. AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2 billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased (-16%) to $114 million. Novartis reported that Femara increased it sell value by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million during 2004. According to UK estimates, the switching of 100 000 women from tamoxifen to Arimidex will cost nearly 100 million. |
|
| Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. Several new approvals have changed the panorama for options in the treatment of late stage prostate cancer. Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer. Additionally, in October 2004 FDA approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in January 2002 for the palliative treatment of advanced prostate cancer. One example of market penetration in this field is that analysts forecasts Abarelix a sales of $450 million in 2006. |
|
| Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells.Scope of this report:In-depth competitive landscape assessment of the apoptopic market in oncologyThorough review of utilized targets in apoptopic drug developmentThorough review of approved drugsProgress analysis of five major cancer indications, including players, drugs, clinical progress and pitfallsResearch and analysis highlights |
|
| With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic chemotherapy agents. |
|
| New approaches in vaccines, such as DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants are being explored. In the last three years the cancer vaccine industry has reshaped itself quite considerably. The number of cancer vaccine players has rather decreased than increased, through operational re-prioritizations, M&As and fall outs. |
|
| Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. |
|
| Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma (NHL). The world prevalence is approximately 650,000 cases, of which 300,000 are low grade and 350,000 are aggressive. The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide thru this field and bring structure and knowledge enable our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan. |
|
